Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roche Nabs FDA Approval for CDx With Ziihera in Gastroesophageal Cancer

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at 360dx.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Roche received FDA approval for expanded use of two companion diagnostic tests with Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) in treating metastatic gastroesophageal adenocarcinoma.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Medtech founders targeting gastroesophageal cancer markets must fast-track regulatory strategies as diagnostic approvals are opening new patient stratification paths that can accelerate therapy adoption and partnerships.

◆ Coverage

1 source · 26 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalcompanion-diagnosticsgastroesophageal-cancerrochezanidatamab